Coya Therapeutics, Inc.
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| – | – | – | – | – | – | |
| – | +0.0% | +69.6% | +0.0% | +0.0% | +0.0% | |
| – | – | -11.1% | +320.7% | +205.4% | +61.1% | |
| – | -41.1% | +1,284.5% | – | – | – | |
| – | +848.2% | +1.7% | -717.7% | – | +106.8% | |
| – | +3,420,000.0% | -100.0% | -75.0% | -100.0% | – | |
| – | +0.0% | +283.8% | +3.5% | -95.4% | +4,558.4% | |
| – | +4,552.9% | +0.0% | -100.0% | – | – | |
| – | -103.7% | – | +310.6% | -58.3% | +27.2% | |
| – | -150.2% | – | +1,575.1% | -78.6% | +48.5% | |
| – | – | – | – | – | – |
Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.